Sinotherapeutics Inc
SSE:688247
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sinotherapeutics Inc
Long-Term Debt
Sinotherapeutics Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sinotherapeutics Inc
SSE:688247
|
Long-Term Debt
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Long-Term Debt
¥47.6m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Long-Term Debt
¥43.3m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Long-Term Debt
¥779.6m
|
CAGR 3-Years
39%
|
CAGR 5-Years
84%
|
CAGR 10-Years
-1%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Long-Term Debt
¥4.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
46%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Long-Term Debt
¥1.2B
|
CAGR 3-Years
129%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sinotherapeutics Inc
Glance View
Sinotherapeutics, Inc. engages in the research and development, production and sales of high-end generic drugs and Contract Research Organization (CRO) services. The company is headquartered in Shanghai, Shanghai and currently employs 248 full-time employees. The company went IPO on 2022-08-25. The firm's main businesses include research and development, production and sales of generic drugs, as well as contract research and development organization (CRO) services. The firm mainly operates in the domestic market and overseas markets.
See Also
What is Sinotherapeutics Inc's Long-Term Debt?
Long-Term Debt
0
CNY
Based on the financial report for Dec 31, 2024, Sinotherapeutics Inc's Long-Term Debt amounts to 0 CNY.
